Skip to main content
. 2016 Feb 14;22(6):2024–2029. doi: 10.3748/wjg.v22.i6.2024

Table 2.

Pulmonary arterial hypertension-specific therapy: A summary of agents used

Entothelin receptor antagonists
Agents used in PoPHT: bosentan, ambrisentan
Mechanism of action: blockade of endothelin receptors
Route of administration: oral
Effects: vasodilation, decrease in PVR and portal pressure
Adverse effects: hepatotoxicity
PDE-5 inhibitors
Agents used in PoPHT: sildenafil, tadalafil, vardenafil
Mechanism of action: inhibition of PDE-5 enzyme
Route of administration: oral
Effects: vasodilation, decrease in portal pressure
Adverse effects: hypotension
Prostacyclins
Agents used in PoPHT: epoprostenol, iloprost
Mechanism of action: prostaglandin analogue, increase in cAMP
Route of administration: epoprostenol IV, iloprost inhalation
Effects: vasodilation, antiaggregation
Adverse effects: flushing, headache, nausea, diarrhea. Problems with IV epoprostenol use: cost, infection, catheter thrombosis, and thrombocytopenia

PAH: Pulmonary arterial hypertension; PoPHT: Portopulmonary hypertension; PDE-5: Phosphodiesterase type 5 enzyme; PVR: Pulmonary vascular resistance; IV: Intravenous.